Dr. McGregor on Combos With Nivolumab, Cabozantinib, and Sunitinib in RCC


In Partnership With:

Bradley McGregor, MD, discusses combination therapies with nivolumab, cabozantinib, and sunitinib in renal cell carcinoma.

Bradley McGregor, MD, clinical director, Lank Center for Genitourinary Oncology, senior physician, Dana-Farber Cancer Institute, and instructor of medicine, Harvard Medical School, discusses combination therapies with nivolumab (Opdivo), cabozantinib (Cabometyx), and sunitinib (Sutent) in renal cell carcinoma (RCC).

There has been a revolution within therapy of RCC in the past couple of years, says McGregor. The initial data from the CheckMate-9ER study showed that the combination of nivolumab and cabozantinib improved overall survival when compared with sunitinib in the frontline setting of patients with intermediate- and poor-risk disease. More recently, there have also been combinations of sunitinib with either pembrolizumab (Keytruda) or durvalumab (Imfinzi), which have shown to improve progression-free survival, and in the case of sunitinib and pembrolizumab, there was an overall survival benefit, as well.

Cabozantinib is a multikinase, small molecule receptor TKI, McGregor added. Data from the CABOSUN study showed efficacy with cabozantinib in the frontline and second-line settings; the drug was compared with sunitinib. I am continuously looking to see if there is an improvement in response rates and the outcomes of patients with RCC in the frontline setting with combination therapy, concludes McGregor.

Related Videos
Jose A. Karam, MD, FACS
Amer Zeidan, MBBS
Eric Jonasch, MD
Ulka Nitin Vaishampayan, MBBS
Erica L. Mayer, MD, MPH
Christopher M. Gallagher, MD
Lyudmila A. Bazhenova, MD
Benjamin Philip Levy, MD
John N. Allan, MD
Nicole Lamanna, MD